Multiple mutations in genes within the ALK‐independent RTK‐KRAS and TP53 pathways, including EGFR, KRAS, and BRAF, have been identified at the single‐cell level in circulating tumour cells (CTCs) of crizotinib‐resistant patients.168. The gene discussed is KRAS; the disease is neoplasm.